42392
document
Safety and efficacy of oral DMSA therapy for children with autism spectrum disorders : part B - behavioral results . BACKGROUND This study investigated the effects of oral dimercapto succinic acid ( DMSA ) therapy on the behavioural symptoms of children with autism spectrum disorders ( ASD ) ages 3-8 years . METHODS Phase 1 involved 65 children with ASD who received one round of DMSA ( 3 days ) . Participants who had high urinary excretion of toxic metals were selected to continue on to phase 2 . In phase 2 , 49 participants were randomly assigned in a double-blind design to receive an additional 6 rounds of either DMSA or placebo . RESULTS The groups receiving one round and seven rounds of DMSA had significant improvements on all the assessment measures . For the seven round group , the degree of improvement on the assessment measures could be partially explained by a regression analysis based on excretion of toxic metals and changes in glutathione ( adjusted R2 of 0.28-0.75 , p < 0.02 in all cases ) . One round of DMSA had nearly the same benefit as seven rounds . The assessment measures correlated reasonably with one another at the beginning of the study ( r = 0.60-0.87 ) and even better at the end of the study ( r = 0.63-0.94 ) . CONCLUSION Overall , both one and seven rounds of DMSA therapy seems to be reasonably safe in children with ASD who have high urinary excretion of toxic metals , and possibly helpful in reducing some of the symptoms of autism in those children .
42393
Intervention_Pharmacological
DMSA
42394
Intervention_Physical
therapy
42395
Intervention_Pharmacological
oral dimercapto succinic acid ( DMSA )
42396
Intervention_Pharmacological
DMSA
42397
Intervention_Control
placebo
42398
Intervention_Pharmacological
DMSA
42399
Intervention_Pharmacological
DMSA
42400
Outcome_Other
Safety and efficacy
42401
Outcome_Physical
improvement
42402
Outcome_Other
assessment measures
42403
Outcome_Physical
excretion of toxic metals and changes in glutathione
42404
Outcome_Other
safe
42405
Participant_Age
children
42406
Participant_Condition
autism spectrum disorders
42407
Participant_Condition
autism spectrum disorders ( ASD
42408
Participant_Age
ages 3-8 years
42409
Participant_Sample-size
65
42410
Participant_Age
children
42411
Participant_Condition
ASD
42412
Participant_Condition
high urinary excretion of toxic metals
42413
Participant_Sample-size
49
42414
Participant_Age
children
42415
Participant_Condition
ASD
42416
Participant_Condition
high urinary excretion of toxic metals